Product Description: Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Lou B, et al. Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer. Front Oncol. 2021 Sep 15;11:736955./[2]Markham A. Zimberelimab: First Approval. Drugs. 2021 Nov;81(17):2063-2068.
CAS Number: 2259860-24-5
Molecular Weight: N/A
Compound Purity: 99.90
Research Area: Cancer
Solubility: H2O
Target: PD-1/PD-L1
English
Deutsch
